GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results